Bambusa Therapeutics has raised $168.9M, the company confirmed, in a round that gives the inflammatory and immunology specialist a sizable war chest.
The Boston-based company is building a portfolio of molecules aimed at chronic and debilitating inflammatory conditions, a field it argues has been overdue for innovative approaches and transformative therapeutics. Bambusa did not disclose the round's structure or its investors.

















